Glucose-6-phosphate dehydrogenase (G6PD) is the rate-limiting enzyme of the pentose phosphate pathway (PPP), catalyzing the oxidation of glucose-6-phosphate to 6-phosphogluconolactone while generating NADPH and ribose-5-phosphate. G6PD is essential for maintaining cellular redox balance by supplying NADPH to regenerate reduced glutathione, protecting cells—especially red blood cells—from oxidative damage. Deficiency in G6PD affects over 400 million people globally, providing malaria resistance through evolutionary balancing selection while causing hemolytic crises under oxidative challenge.
Think of G6PD as the battery charger for your cellular antioxidant system. Red blood cells are like delivery trucks without repair shops—they can't make new parts or generate energy any other way except through glucose breakdown. G6PD runs a side factory (the pentose phosphate pathway) off the main glucose highway, producing NADPH—the "charged batteries" that keep glutathione ready to neutralize free radicals. When you have G6PD deficiency, it's like running delivery trucks with a broken battery charger: everything works fine in normal traffic, but hit a storm of Oxidative Stress (infection, certain drugs, fava beans) and the batteries drain faster than they can recharge. Older red blood cells are most vulnerable—they're the aging trucks whose chargers have worn out after months on the road. Meanwhile, white blood cells use the same NADPH batteries, but for the opposite purpose: neutrophils deliberately drain them through NADPH oxidase to create a toxic burst that kills bacteria. G6PD deficiency is nature's compromise: weaker oxidative burst means slower bacterial killing but also prevents malaria parasites from thriving in red blood cells, because the parasites generate oxidative stress that collapses deficient cells before the parasite can multiply.
G6PD catalyzes the first and committed step of the oxidative phase of the pentose phosphate pathway:
Enzymatic mechanism:
G6PD + Glucose-6-P + NADP+ → G6PD + 6-Phosphogluconolactone + NADPH + H+
The reaction is essentially irreversible under physiological conditions (ΔG°' = -17.6 kJ/mol), making it the rate-limiting step. G6PD exists as a dimer or tetramer; enzyme activity depends on NADP+ availability and is product-inhibited by NADPH (competitive inhibition at NADP+ binding site).
Downstream NADPH utilization pathways:
Antioxidant defense: NADPH reduces oxidized glutathione (GSSG) via glutathione reductase → 2 GSH. GSH then reduces H2O2 and lipid peroxides via glutathione peroxidase, maintaining redox balance. In G6PD deficiency, GSSG accumulates, GSH depletes, and oxidative damage targets hemoglobin (forming Heinz bodies), membrane lipids, and cytoskeletal proteins.
Immune oxidative burst: Neutrophils, monocytes, and macrophages use NADPH oxidase (NOX2 complex: gp91phox + p22phox + p47phox + p67phox + Rac2) to generate superoxide (O2•−) from O2. Superoxide dismutates to H2O2, which forms hypochlorous acid (HOCl) via myeloperoxidase—the microbicidal cocktail of respiratory burst. G6PD-deficient individuals have reduced NOX2 activity and impaired pathogen killing.
Biosynthesis: NADPH is required for fatty acid synthesis (via fatty acid synthase), cholesterol synthesis (via HMG-CoA reductase pathway), nucleotide synthesis (via ribonucleotide reductase), and neurotransmitter synthesis (via tyrosine hydroxylase, tryptophan hydroxylase).
Regulatory nodes:
Nrf2 pathway: Oxidative Stress → Keap1 oxidation → Nrf2 nuclear translocation → binding to antioxidant response elements (AREs) in G6PD promoter → increased transcription. This creates a negative feedback loop: oxidative stress upregulates the enzyme that generates antioxidant capacity.
HIF-1α pathway: Hypoxia stabilizes HIF-1α → dimerization with HIF-1β → binding to hypoxia response elements (HREs) in G6PD promoter → increased expression. This links oxygen sensing to redox control, as hypoxic cells face mitochondrial ROS generation and need enhanced NADPH production.
NADP+/NADPH ratio: High NADPH product-inhibits G6PD; low NADP+ substrate-limits the reaction. This ensures the pathway only runs when reducing power is needed.
Red blood cell vulnerability: Mature RBCs lack mitochondria, nucleus, and ribosomes—they cannot perform oxidative phosphorylation, synthesize new proteins, or upregulate antioxidant defenses. The pentose phosphate pathway via G6PD is their ONLY source of NADPH. G6PD activity declines as RBCs age (120-day lifespan), making older cells most susceptible to hemolysis during oxidative stress. G6PD variants are classified by residual enzyme activity: Class I (<10%, severe), Class II (10-60%, moderate), Class III (60-150%, mild deficiency to normal).
Evolutionary balancing selection: G6PD deficiency is the most common human enzyme deficiency (prevalence 4-26% in malaria-endemic regions) due to heterozygote advantage. Deficient RBCs undergo oxidative stress-induced hemolysis when infected by Plasmodium falciparum, limiting parasite replication and transmission. This provides ~50% protection against severe malaria and cerebral malaria, explaining why the mutation persists despite hemolytic risk. Heterozygous females gain protection with minimal hemolytic liability due to X-inactivation mosaicism.
Hemolytic crisis triggers in cPNI practice:
Infection: Bacterial and viral infections generate inflammation, cytokine release (IL-6, TNF-α), and immune-driven ROS production. Fever increases metabolic rate and oxidative metabolism. The combination overwhelms depleted GSH reserves, causing acute hemolytic anemia 2-4 days post-infection onset. Clinical signs: jaundice, dark urine (hemoglobinuria), pallor, tachycardia, hemoglobin drop >2 g/dL.
Oxidizing drugs: Avoid primaquine, dapsone, sulfonamides, nitrofurantoin, rasburicase, methylene blue (ironically used as antidote in methemoglobinemia but contraindicated in G6PD deficiency), high-dose aspirin (>3 g/day), phenazopyridine. NSAIDs at standard doses are generally safe.
Fava beans (favism): Vicine and convicine in Vicia faba generate oxidative metabolites (divicine, isouramil) that deplete GSH and cause severe hemolysis in Mediterranean G6PD variants within hours of ingestion. Not all G6PD-deficient individuals develop favism—genetic modifiers influence susceptibility.
High-dose vitamin C: Doses >1000 mg/day can act as pro-oxidant in G6PD deficiency, especially intravenous administration. Vitamin C reduces Fe3+ to Fe2+, promoting Fenton reaction (Fe2+ + H2O2 → Fe3+ + OH• + OH−), generating hydroxyl radicals. Standard dietary intake is safe.
Neonatal jaundice: G6PD-deficient newborns have 2-3× higher risk of severe hyperbilirubinemia requiring phototherapy. Birth itself is an oxidative transition (from hypoxic intrauterine environment to normoxic extrauterine), and neonatal RBCs have shorter lifespan. Screen in high-risk populations.
cPNI clinical implications:
Immune function trade-offs: Reduced respiratory burst capacity means longer duration of infection and potentially higher reliance on adaptive immunity (T cell responses). However, reduced oxidative burst may lower chronic low-grade inflammation in some contexts—a double-edged sword.
Metabolic flexibility constraints: G6PD-deficient individuals may have impaired capacity to handle repeated metabolic stress (e.g., intense exercise, fasting, ketogenic transitions) if antioxidant systems are already compromised. The pentose phosphate pathway also generates ribose-5-phosphate for nucleotide synthesis—essential for cell division and tissue repair.
Cancer cell vulnerability: Many cancer cells upregulate G6PD to support rapid proliferation, NADPH-dependent biosynthesis, and redox management. Therapeutic G6PD inhibition (e.g., dehydroepiandrosterone, 6-aminonicotinamide) is under investigation as an anti-cancer strategy, exploiting cancer's oxidative vulnerability.
Hypoxia adaptation: HIF-1α upregulates G6PD during hypoxia, linking oxygen sensing to redox control. This is relevant in high-altitude adaptation, chronic lung disease, and tissue ischemia. G6PD-deficient individuals may have blunted hypoxic adaptation.
Chronic inflammation and aging: Chronic oxidative stress (from metabolic syndrome, smoking, pollution) progressively depletes antioxidant capacity. G6PD-deficient individuals may age faster in oxidative-stress-rich environments—an evolutionary mismatch scenario.
Diagnostic thresholds:
Intervention strategies: